Authors' reply

The Lancet

Volumn 383, Issue 9912, 2014, Pages 122-

  Bhala, Neeraj ^a   Emberson, Jonathan ^a   Patrono, Carlo ^b   Baigent, Colin ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGING; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; NOTE; VASCULAR DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS; VASCULAR DISEASES;

EID: 84892171690     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/s0140-6736(14)60017-9     Document Type: Letter

References (1)

1. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffi eld Department of Population Health, Oxford OX3 7LF, UK (NB, JE, CB); and Institute of Pharmacology, Catholic University of the Sacred Heart, Rome, Italy (CP) 1 Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal eff ects of non-steroidal anti-infl ammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet 2013; 382: 769-79.